{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:00:54Z","timestamp":1790204454520,"version":"4.1.0"},"reference-count":108,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:00:00Z","timestamp":1489708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The objective of this study was to review the role of bilateral salpingo-oophorectomy in BRCA mutation (mBRCA) carriers and alternative interventions in risk reduction of ovarian cancer (OC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>A systematic review using PubMed, MEDLINE, EMBASE, and the Cochrane library was conducted to identify studies of different strategies to prevent OC in mBRCA carriers, including bilateral salpingo-oophorectomy, prophylactic salpingectomy with delayed oophorectomy, intensive surveillance, and chemoprevention.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Risk-reducing bilateral salpingo-oophorectomy is an effective intervention, but its associated morbidity is substantial and seems to curtail uptake rates among the target population. Although there is much interest and a strong theoretical basis for salpingectomy with delayed oophorectomy, data on its clinical application are scarce with regard to screening, the use of an algorithmic protocol has recently shown favorable albeit indefinite results in average-risk postmenopausal women. Its incorporation into studies focused on high-risk women might help solidify a future role for screening as a bridge to surgery. The use of oral contraceptives for chemoprevention is well supported by epidemiologic studies. However, there is a lack of evidence for advocating any of the other agents proposed for this purpose, including nonsteroidal anti-inflammatory drugs, vitamin D, and retinoids.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Further studies are needed before salpingectomy with delayed oophorectomy or intensive surveillance can be offered as acceptable, less morbid alternatives to upfront oophorectomy for mBRCA carriers.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0444","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T02:58:25Z","timestamp":1489805905000},"page":"450-459","source":"Crossref","is-referenced-by-count":42,"title":["Risk-Reducing Strategies for Ovarian Cancer in <i>BRCA<\/i> Mutation Carriers: A Balancing Act"],"prefix":"10.1093","volume":"22","author":[{"given":"Roi","family":"Tschernichovsky","sequence":"first","affiliation":[{"name":"Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annekathryn","family":"Goodman","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Boston, Massachusetts, USA"},{"name":"Department of Obstetrics and Gynecology Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"key":"2021122507531922000_onco12079-bib-0001","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"2021122507531922000_onco12079-bib-0002","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bpobgyn.2005.10.007","article-title":"Worldwide burden of gynaecological cancer: The size of the problem","volume":"20","author":"Sankaranarayanan","year":"2006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2021122507531922000_onco12079-bib-0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ygyno.2010.06.003","article-title":"SGO White Paper on ovarian cancer: Etiology, screening and surveillance","volume":"119","author":"Schorge","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2021122507531922000_onco12079-bib-0004","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"2021122507531922000_onco12079-bib-0005","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122507531922000_onco12079-bib-0006","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2021122507531922000_onco12079-bib-0007","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/AOG.0b013e3181a106d4","article-title":"ACOG practice bulletin no. 103: Hereditary breast and ovarian cancer syndrome","volume":"113","author":"American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins\u2013Gynecology; ACOG Committee on Genetics","year":"2009","journal-title":"Obstet Gynecol"},{"key":"2021122507531922000_onco12079-bib-0008","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.maturitas.2011.08.001","article-title":"Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review","volume":"70","author":"Finch","year":"2011","journal-title":"Maturitas"},{"key":"2021122507531922000_onco12079-bib-0009","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2021122507531922000_onco12079-bib-0010","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domcheck","year":"2010","journal-title":"JAMA"},{"key":"2021122507531922000_onco12079-bib-0011","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122507531922000_onco12079-bib-0012","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12905-014-0150-5","article-title":"Risk-reducing salpingo-oophorectomy: A meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers","volume":"14","author":"Marchetti","year":"2014","journal-title":"BMC Womens Health"},{"key":"2021122507531922000_onco12079-bib-0013","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/jnci\/91.17.1475","article-title":"Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers","volume":"17","author":"Rebbeck","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"2021122507531922000_onco12079-bib-0014","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N Engl J Med"},{"key":"2021122507531922000_onco12079-bib-0015","doi-asserted-by":"crossref","first-page":"8629","DOI":"10.1200\/JCO.2005.02.9199","article-title":"Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers","volume":"23","author":"Kramer","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122507531922000_onco12079-bib-0016","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","article-title":"Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An international case-control study","volume":"23","author":"Eisen","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122507531922000_onco12079-bib-0017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(06)70585-X","article-title":"Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study","volume":"7","author":"Domcheck","year":"2006","journal-title":"Lancet Oncol"},{"key":"2021122507531922000_onco12079-bib-0018","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122507531922000_onco12079-bib-0019","article-title":"Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers","author":"Kotsopoulos","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2021122507531922000_onco12079-bib-0020","doi-asserted-by":"crossref","first-page":"djv033","DOI":"10.1093\/jnci\/djv033","article-title":"Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: Revisiting the evidence for risk reduction","volume":"107","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2021122507531922000_onco12079-bib-0021","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1006\/gyno.2002.6853","article-title":"Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women","volume":"88","author":"Menczer","year":"2003","journal-title":"Gynecol Oncol"},{"key":"2021122507531922000_onco12079-bib-0022","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.ajog.2004.04.028","article-title":"Surgical risk reduction: Prophylactic salpingo-oophorectomy and prophylactic mastectomy","volume":"191","author":"Dowdy","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"2021122507531922000_onco12079-bib-0023","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"2021122507531922000_onco12079-bib-0024","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0090-8258(03)00072-6","article-title":"Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy","volume":"89","author":"Robson","year":"2003","journal-title":"Gynecol Oncol"},{"key":"2021122507531922000_onco12079-bib-0025","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1200\/JCO.2005.02.626","article-title":"Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer","volume":"23","author":"Madalinska","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122507531922000_onco12079-bib-0026","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.2005.05.1896","article-title":"The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy","volume":"24","author":"Madalinska","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122507531922000_onco12079-bib-0027","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2010.12.326","article-title":"The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation","volume":"121","author":"Finch","year":"2011","journal-title":"Gynecol Oncol"},{"key":"2021122507531922000_onco12079-bib-0028","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ygyno.2015.11.016","article-title":"Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy","volume":"140","author":"Johansen","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2021122507531922000_onco12079-bib-0029","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.mayocp.2016.08.002","article-title":"Accelerated accumulation of multimorbidity after bilateral oophorectomy: A population-based cohort study","volume":"91","author":"Rocca","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2021122507531922000_onco12079-bib-0030","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1097\/AOG.0b013e3181a11c64","article-title":"Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses\u2019 health study","volume":"113","author":"Parker","year":"2009","journal-title":"Obstet Gynecol"},{"key":"2021122507531922000_onco12079-bib-0031","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1212\/01.wnl.0000276984.19542.e6","article-title":"Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause","volume":"69","author":"Rocca","year":"2007","journal-title":"Neurology"},{"key":"2021122507531922000_onco12079-bib-0032","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1212\/01.wnl.0000280573.30975.6a","article-title":"Increased risk of parkinsonism in women who underwent oophorectomy before menopause","volume":"70","author":"Rocca","year":"2008","journal-title":"Neurology"},{"key":"2021122507531922000_onco12079-bib-0033","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1097\/gme.0b013e318174f155","article-title":"Long-term risk of depressive and anxiety symptoms after early bilateral oophorectomy","volume":"15","author":"Rocca","year":"2008","journal-title":"Menopause"},{"key":"2021122507531922000_onco12079-bib-0034","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","volume":"2","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"key":"2021122507531922000_onco12079-bib-0035","doi-asserted-by":"crossref","first-page":"917","DOI":"10.6004\/jnccn.2015.0106","article-title":"Menopausal hormone therapy influence on breast cancer outcomes in the women\u2019s health initiative","volume":"13","author":"Chlebowski","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122507531922000_onco12079-bib-0036","article-title":"Is hormone replacement therapy safe in women with a BRCA mutation?: A systematic review of the contemporary literature","author":"Birrer","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"2021122507531922000_onco12079-bib-0037","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/GME.0000000000000724","article-title":"Use of systemic hormone therapy in BRCA mutation carriers","volume":"23","author":"Domchek","year":"2016","journal-title":"Menopause"},{"key":"2021122507531922000_onco12079-bib-0038","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122507531922000_onco12079-bib-0039","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","article-title":"Influence of estrogen plus progestin on breast cancer and mammography in healthy postmeonopausal women: The Women\u2019s Health Initiative Randomized Trial","volume":"289","author":"Chlebowski","year":"2003","journal-title":"JAMA"},{"key":"2021122507531922000_onco12079-bib-0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3109\/01674829309084451","article-title":"Elective ovarian removal and estrogen replacement therapy\u2013effects on sexual life, psychological well-being and androgen status","volume":"14","author":"Nathorst-B\u00f6\u00f6s","year":"1993","journal-title":"J Psychosom Obstet Gynaecol"},{"key":"2021122507531922000_onco12079-bib-0041","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1399-0004.2006.00665.x","article-title":"Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: A prospective cohort study","volume":"70","author":"Phillips","year":"2006","journal-title":"Clin Genet"},{"key":"2021122507531922000_onco12079-bib-0042","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1399-0004.2009.01329.x","article-title":"Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: Uptake and timing","volume":"77","author":"Skytte","year":"2010","journal-title":"Clin Genet"},{"key":"2021122507531922000_onco12079-bib-0043","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/GIM.0b013e318163487d","article-title":"Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers","volume":"10","author":"Bradbury","year":"2008","journal-title":"Genet Med"},{"key":"2021122507531922000_onco12079-bib-0044","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-09-2953","article-title":"New strategies in ovarian cancer: Uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy","volume":"16","author":"Miller","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"suppl 8","key":"2021122507531922000_onco12079-bib-0045","doi-asserted-by":"crossref","first-page":"viii47","DOI":"10.1093\/annonc\/mdt311","article-title":"Alternatives to risk-reducing surgery for ovarian cancer","volume":"24","author":"Gadducci","year":"2013","journal-title":"Ann Oncol"},{"key":"2021122507531922000_onco12079-bib-0046","doi-asserted-by":"crossref","first-page":"djt453","DOI":"10.1093\/jnci\/djt453","article-title":"Aspirin in prevention of ovarian cancer: Are we at the tipping point?","volume":"106","author":"Tsoref","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2021122507531922000_onco12079-bib-0047","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/ije\/dyw207","article-title":"Association of vitamin D levels and risk of ovarian cancer: Mendelian randomization study","volume":"45","author":"Ong","year":"2016","journal-title":"Int J Epidemiol"},{"key":"2021122507531922000_onco12079-bib-0048","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2005.04.109","article-title":"Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy","volume":"23","author":"Powell","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122507531922000_onco12079-bib-0049","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/IGC.0b013e31821bc7e3","article-title":"Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: Experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol","volume":"21","author":"Powell","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"2021122507531922000_onco12079-bib-0050","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/01.pas.0000202161.80739.ac","article-title":"Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions","volume":"30","author":"Carcangiu","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"2021122507531922000_onco12079-bib-0051","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2005.06.065","article-title":"Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers","volume":"100","author":"Finch","year":"2006","journal-title":"Gynecol Oncol"},{"key":"2021122507531922000_onco12079-bib-0052","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.2007.12.2622","article-title":"Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction","volume":"25","author":"Callahan","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122507531922000_onco12079-bib-0053","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"2021122507531922000_onco12079-bib-0054","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GCO.0b013e328011a21f","article-title":"The distal fallopian tube: A new model for pelvic serous carcinogenesis","volume":"19","author":"Crum","year":"2007","journal-title":"Curr Opin Obstet Gynecol"},{"key":"2021122507531922000_onco12079-bib-0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"2021122507531922000_onco12079-bib-0056","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1200\/JCO.2008.16.4814","article-title":"Serous tubal intraepithelial carcinoma: Its potential role in primary peritoneal serous carcinoma and serous cancer prevention","volume":"26","author":"Carlson","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122507531922000_onco12079-bib-0057","doi-asserted-by":"crossref","first-page":"19.e1","DOI":"10.1016\/j.ajog.2010.05.038","article-title":"Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1\/2 mutation carriers?","volume":"204","author":"Greene","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"2021122507531922000_onco12079-bib-0058","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/IGC.0b013e3182849dba","article-title":"Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer","volume":"23","author":"Anderson","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"2021122507531922000_onco12079-bib-0059","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fonc.2014.00021","article-title":"Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: A mini-review","volume":"4","author":"Schenberg","year":"2014","journal-title":"Front Oncol"},{"key":"2021122507531922000_onco12079-bib-0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1757-2215-5-13","article-title":"Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis","volume":"5","author":"Rice","year":"2012","journal-title":"J Ovarian Res"},{"key":"2021122507531922000_onco12079-bib-0061","doi-asserted-by":"crossref","first-page":"dju410","DOI":"10.1093\/jnci\/dju410","article-title":"Ovarian cancer risk after salpingectomy: A nationwide population-based study","volume":"107","author":"Falconer","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2021122507531922000_onco12079-bib-0062","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1093\/humrep\/der337","article-title":"The fimbria\/ovarian surface junction","volume":"26","author":"Dietl","year":"2011","journal-title":"Hum Reprod"},{"key":"2021122507531922000_onco12079-bib-0063","doi-asserted-by":"crossref","first-page":"471.e1","DOI":"10.1016\/j.ajog.2014.01.003","article-title":"Opportunistic salpingectomy: Uptake, risks, and complications of a regional initiative for ovarian cancer prevention","volume":"210","author":"McAlpine","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"2021122507531922000_onco12079-bib-0064","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/humrep\/der274","article-title":"The post-reproductive fallopian tube: Better removed?","volume":"26","author":"Dietl","year":"2011","journal-title":"Hum Reprod"},{"key":"2021122507531922000_onco12079-bib-0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/AOG.0b013e3182783c2f","article-title":"Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers","volume":"121","author":"Kwon","year":"2013","journal-title":"Obstet Gynecol"},{"key":"2021122507531922000_onco12079-bib-0066","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1097\/AOG.0000000000001448","article-title":"Salpingectomy with delayed oophorectomy in BRCA1\/2 mutation carriers: Estimating ovarian cancer risk","volume":"127","author":"Harmsen","year":"2016","journal-title":"Obstet Gynecol"},{"key":"2021122507531922000_onco12079-bib-0067","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ygyno.2011.02.012","article-title":"Radical fimbriectomy: A reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development","volume":"121","author":"Leblanc","year":"2011","journal-title":"Gynecol Oncol"},{"key":"2021122507531922000_onco12079-bib-0068","author":"Centre Oscar Lambret","year":"2016"},{"key":"2021122507531922000_onco12079-bib-0069","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.gynor.2014.05.002","article-title":"First case of prophylactic salpingectomy with single port access laparoscopy and a new diode laser in a woman with BRCA mutation","volume":"9","author":"Angioni","year":"2014","journal-title":"Gynecol Oncol Case Rep"},{"key":"2021122507531922000_onco12079-bib-0070","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1002\/cncr.29321","article-title":"Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer","volume":"121","author":"Walker","year":"2015","journal-title":"Cancer"},{"key":"2021122507531922000_onco12079-bib-0071","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2014.02.030","article-title":"Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers","volume":"133","author":"Holman","year":"2014","journal-title":"Gynecol Oncol"},{"key":"2021122507531922000_onco12079-bib-0072","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10689-015-9823-y","article-title":"Risk reducing salpingetomy and delayed oophorectomy in high risk women: Views of cancer geneticists, genetic counsellors and gynaecologic oncologists in the UK","volume":"14","author":"Chandrasekaran","year":"2015","journal-title":"Fam Cancer"},{"key":"2021122507531922000_onco12079-bib-0073","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ygyno.2014.12.031","article-title":"Risk-reducing salpingectomy with delayed oophorectomy in BRCA1\/2 mutation carriers: Patients\u2019 and professionals\u2019 perspectives","volume":"136","author":"Arts-de Jong","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2021122507531922000_onco12079-bib-0074","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1186\/s12885-015-1597-y","article-title":"Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1\/2 mutation carriers (TUBA study): A prospective non-randomised multicentre study","volume":"15","author":"Harmsen","year":"2015","journal-title":"BMC Cancer"},{"key":"2021122507531922000_onco12079-bib-0075","author":"M.D. Anderson Cancer Center","year":"2016"},{"key":"2021122507531922000_onco12079-bib-0076","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11864-016-0396-2","article-title":"Options in prophylactic surgery to prevent ovarian cancer in high-risk women: How new hypotheses of fallopian tube origin influence recommendations","volume":"17","author":"Swanson","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"2021122507531922000_onco12079-bib-0077","author":"National Comprehensive Cancer Network","year":"2016"},{"key":"2021122507531922000_onco12079-bib-0078","author":"U.S. Food and Drug Administration","year":"2016"},{"key":"2021122507531922000_onco12079-bib-0079","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.bjc.6603725","article-title":"No efficacy of annual gynaecological screening in BRCA1\/2 mutation carriers; an observational follow-up study","volume":"96","author":"Hermsen","year":"2007","journal-title":"Br J Cancer"},{"key":"2021122507531922000_onco12079-bib-0080","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/jmg.2008.058248","article-title":"Screening for familial ovarian cancer: Poor survival of BRCA1\/2 related cancers","volume":"46","author":"Evans","year":"2009","journal-title":"J Med Genet"},{"key":"2021122507531922000_onco12079-bib-0081","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1200\/JCO.2011.39.7638","article-title":"Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule","volume":"31","author":"Rosenthal","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122507531922000_onco12079-bib-0082","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"2021122507531922000_onco12079-bib-0083","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/S0140-6736(16)30847-9","article-title":"Ovarian cancer screening: UKCTOCS trial","volume":"387","author":"Sasieni","year":"2016","journal-title":"Lancet"},{"key":"2021122507531922000_onco12079-bib-0084","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1055-9965.EPI-07-2703","article-title":"A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: Design and baseline characteristics: A Gynecologic Oncology Group study. Cancer","volume":"17","author":"Greene","year":"2008","journal-title":"Epidemiol Biomarkers Prev"},{"key":"2021122507531922000_onco12079-bib-0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R","year":"2008","journal-title":"Lancet"},{"key":"2021122507531922000_onco12079-bib-0086","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: A meta-analysis","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur J Cancer"},{"key":"2021122507531922000_onco12079-bib-0087","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies","volume":"347","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"1996","journal-title":"Lancet"},{"key":"2021122507531922000_onco12079-bib-0088","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","article-title":"Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: A systematic review and meta-analysis","volume":"31","author":"Moorman","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122507531922000_onco12079-bib-0089","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ygyno.2016.08.318","article-title":"Increased risk of borderline ovarian tumors in women with a history of pelvic inflammatory disease: A nationwide population-based cohort study","volume":"143","author":"Rasmussen","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2021122507531922000_onco12079-bib-0090","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S1470-2045(11)70165-6","article-title":"Risk of ovarian cancer in women with pelvic inflammatory disease: A population-based study","volume":"12","author":"Lin","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122507531922000_onco12079-bib-0091","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/1940-6207.CAPR-11-0391","article-title":"Aspirin in the chemoprevention of colorectal neoplasia: An overview","volume":"5","author":"Chan","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"key":"2021122507531922000_onco12079-bib-0092","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/annonc\/mds113","article-title":"Aspirin and cancer risk: A quantitative review to 2011","volume":"23","author":"Bosetti","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122507531922000_onco12079-bib-0093","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3892\/ol.2016.4607","article-title":"Aspirin inhibits growth of ovarian cancer by upregulating caspase 3 and downregulating bcl-2","volume":"12","author":"Li","year":"2016","journal-title":"Oncol Lett"},{"key":"2021122507531922000_onco12079-bib-0094","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2125.2012.04290.x","article-title":"Meta-analysis on the association between non-steroidal anti-inflammatory drug use and ovarian cancer","volume":"75","author":"Ni","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2021122507531922000_onco12079-bib-0095","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/aogs.12069","article-title":"Nonsteroidal anti- inflammatory drugs and risk of ovarian cancer: Systematic review and meta-analysis of observational studies","volume":"92","author":"Baandrup","year":"2013","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2021122507531922000_onco12079-bib-0096","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ygyno.2016.04.543","article-title":"Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis","volume":"142","author":"Zhang","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2021122507531922000_onco12079-bib-0097","doi-asserted-by":"crossref","first-page":"djt431","DOI":"10.1093\/jnci\/djt431","article-title":"Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: A pooled analysis in the Ovarian Cancer Association Consortium","volume":"106","author":"Trabert","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2021122507531922000_onco12079-bib-0098","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2147\/OTT.S100581","article-title":"Vitamin D postpones the progression of epithelial ovarian cancer induced by 7, 12-dimethylbenz [a] anthracene both in vitro and in vivo","volume":"19","author":"Liu","year":"2016","journal-title":"Onco Targets Ther"},{"key":"2021122507531922000_onco12079-bib-0099","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13048-016-0235-x","article-title":"Vitamin D3 stimulates embryonic stem cells but inhibits migration and growth of ovarian cancer and teratocarcinoma cell lines","volume":"9","author":"Abdelbaset-Ismail","year":"2016","journal-title":"J Ovarian Res"},{"key":"2021122507531922000_onco12079-bib-0100","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2010.01.062","article-title":"A systematic literature review of vitamin D and ovarian cancer","volume":"203","author":"Cook","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"2021122507531922000_onco12079-bib-0101","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ygyno.2011.01.023","article-title":"Meta-analysis: Circulating vitamin D and ovarian cancer risk","volume":"121","author":"Yin","year":"2011","journal-title":"Gynecol Oncol"},{"key":"2021122507531922000_onco12079-bib-0102","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D","article-title":"Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression","volume":"65","author":"Supino","year":"1996","journal-title":"Int J Cancer"},{"key":"2021122507531922000_onco12079-bib-0103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/gyno.2002.6663","article-title":"Effect of fenretinide on ovarian carcinoma occurrence","volume":"86","author":"Palo","year":"2002","journal-title":"Gynecol Oncol"},{"key":"2021122507531922000_onco12079-bib-0104","author":"Howick","year":"2016"},{"key":"2021122507531922000_onco12079-bib-0105","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","author":"Burns","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"2021122507531922000_onco12079-bib-0106","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2021122507531922000_onco12079-bib-0107","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1245\/s10434-015-4715-9","article-title":"Chemoprevention for breast cancer","volume":"22","author":"Pruthi","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2021122507531922000_onco12079-bib-0108","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(00)04642-0","article-title":"Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study","volume":"357","author":"Narod","year":"2001","journal-title":"Lancet"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0444","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0444","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/4\/450\/41915916\/oncolo_22_4_450.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/4\/450\/41915916\/oncolo_22_4_450.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:55:08Z","timestamp":1640418908000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/4\/450\/6438801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":108,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,3,17]]},"published-print":{"date-parts":[[2017,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0444","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,4,1]]},"published":{"date-parts":[[2017,3,17]]}}}